Alzheimer’s disease in the real world: Where evidence matters most
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
When billed and allowed amounts aren’t enough: HealthVerity proprietary market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
Insights from IMPACCT 2025: advancing real-world evidence
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
Trusted by the NSF: How HealthVerity set the standard for secure data linkage
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
Understanding the breast cancer patient journey in 2025
October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring...
How AI is changing epidemiology and real-world evidence
In just a few years, artificial intelligence (AI) has become a trusted tool in early drug...
How taXonomy Pathways builds comprehensive patient journeys
In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic...
RWE with transparent AI: Insights from the HealthVerity eXOs webinar
When we introduced HealthVerity eXOs, an agentic AI platform powered by Medeloop, in our recent...
Real-world data for heart failure: Closing evidence gaps across the patient journey
The evolution of heart failure treatment and research Heart failure remains one of the most...
GLP‑1 real‑world data for obesity: A new standard for metabolic care
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Back to breakthrough data: HealthVerity Marketplace for healthcare data
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...